Biomaterial Database

[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)]. 1981

H Bruneder, and H J Klein

The efficacy of bezafibrate in the treatment of hyperlipoproteinaemia was investigated in a controlled therapeutic study and compared with "essential" phospholipids (EPL) and placebo. The investigation involved 120 patients, 87 trial protocols could be evaluated statistically. During pretreatment with bezafibrate for three months cholesterol, triglycerides and fasting blood sugar decreased significantly, HDL-cholesterol increased significantly. During continued treatment with bezafibrate the investigated parameters remained at their achieved levels, whereas with both EPL and placebo there was a renewed increase of cholesterol, triglycerides, fasting blood sugar and HbA1 and a decrease of HDL-cholesterol to values before bezafibrate treatment. There were no differences between placebo and EPL. Both bezafibrate and EPL were tolerated well.

UI	MeSH Term	Description	Entries
D006951	Hyperlipoproteinemias	Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.	Hyperlipoproteinemia
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010743	Phospholipids	Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.	Phosphatides,Phospholipid
D010919	Placebos	Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol.	Sham Treatment
D001786	Blood Glucose	Glucose in blood.	Blood Sugar,Glucose, Blood,Sugar, Blood
D002784	Cholesterol	The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.	Epicholesterol
D002994	Clofibrate	A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)	Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D002995	Clofibric Acid	An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.	Clofibrinic Acid,2-(4-Chlorophenoxy)-2-methylpropionic Acid,NSC-1149,p-Chlorophenoxyisobutyrate,p-Chlorophenoxyisobutyric Acid,NSC 1149,NSC1149
D005260	Female		Females